May 17, 2017 21:08 pm UTC| Business
-31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- -ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC...
Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer
May 17, 2017 21:07 pm UTC| Business
Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initiated in second half of 2017 exploring two metastatic breast cancer populations: HER2-positive...
May 17, 2017 21:05 pm UTC| Business
AMES, Iowa, May 17, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with...
May 17, 2017 21:05 pm UTC| Business
BOULDER, Colo., May 17, 2017 -- Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that new...
May 17, 2017 21:05 pm UTC| Business
NEW YORK, May 17, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 53rd Annual Meeting of the...
Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
May 17, 2017 21:02 pm UTC| Business
HAMPTON, N.J., May 17, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic...
Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
May 17, 2017 21:02 pm UTC| Business
HAMPTON, N.J., May 17, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic...